Factors Affecting Long-Term Safety of Trastuzumab in Patients with Early HER2-Positive Breast Cancer

Boekhout AH^1*, Werkhoven ED², Liebergen R³, Korse CM⁴, Burylo A⁵, Trip AK⁶, Beijnen JH^7,8 and Schellens JH^1,8

¹Division of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands

²Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands

³Department of Cardiology, Slotervaart Hospital, Amsterdam, The Netherlands

⁴Department of Clinical Chemistry, Netherlands Cancer Institute, Amsterdam, The Netherlands

⁵Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands

⁶Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands

⁷Department of Pharmaceutical Sciences, Science Faculty Utrecht University, Utrecht, The Netherlands

⁸Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands